Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Centrexion Therapeutics (United States) | Researchclopedia

Back to institutions

Centrexion Therapeutics (United States)

Boston, Massachusettscompany

39

Works

2,977

Citations

21

h-index

Top Research Topics

Pain Mechanisms and Treatments Osteoarthritis Treatment and Mechanisms Inflammatory mediators and NSAID effects

Top Researchers

Kieren A. Marr Johns Hopkins University

312 works60,225 citationsh-index: 95

Recent Research

Burden of adverse transplant outcomes in kidney transplant recipients with COVID-19 and invasive fungal infections: a retrospective cohort study

Lucy X. Li,Jiashu Xue,et al.

20260 citations

Ion Channels and Receptors

Health Systems, Economic Evaluations, Quality of Life

Analytical Methods in Pharmaceuticals

Ion channel regulation and function

Opioid Use Disorder Treatment

CRISPR and Genetic Engineering

Sphingolipid Metabolism and Signaling

Exercise and Physiological Responses

Pharmaceutical industry and healthcare

John Campbell University of Exeter

784 works30,545 citationsh-index: 89

Jens R. Wendland Centrexion Therapeutics (United States)

101 works20,617 citationsh-index: 48

Markus Warmuth Jnana Therapeutics (United States)

182 works18,769 citationsh-index: 44

James N. Campbell University of Kentucky

216 works14,030 citationsh-index: 59

Robert R. Allen Allen Hospital

75 works9,594 citationsh-index: 21

A phase 1 study to evaluate the safety and tolerability of BXQ-350, a novel sphingolipid metabolism modulator, in pediatric diffuse intrinsic pontine glioma and diffuse midline glioma.

Tariq Arshad,Michael Gazda,et al.

20250 citations

Effect of BXQ-350, a novel sphingolipid metabolism modulator, on neuronal environments through modulation of gene pathways.

Michael Gazda,Tariq Arshad,et al.

20250 citations

BXQ-350, a novel sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal cancer (mCRC) patients: A phase 1b/2 randomized study.

Daniel Flora,Reema Patel,et al.

20250 citations

Response to Commentaries

William P. Horan,Amir H Kalali,et al.

20251 citations

Identification of TUBB3 as an immunotherapy target in lung cancer by genome wide in vivo CRISPR screening

Dan Zhao,Ravindra Pramod Deshpande,et al.

20249 citations